NCT04604613Active, not recruiting
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
Prediction of Recurrence Among Low Risk Endometrial Cancer Population
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
This study investigates whether molecular testing can help to predict the risk of endometrial cancer coming back (recurrence) after treatment in patients diagnosed with low risk endometrial cancer and scheduled to have surgery to remove the uterus and/or cervix (hysterectomy). Having sentinel lymph node mapping performed may help researchers to see if the cancer has spread in patients with low risk endometrial cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 518 (actual)
- First submitted
- 21 Oct 2020
- Start date
- 8 Nov 2012
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Endometrial cancer, Childhood cancers
- NCT number
- NCT04604613
What you commit to
- Study type: Observational
- Participants enrolled: 518
- From 8 Nov 2012 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medical co-morbidities making surgery unsafe, as determined by the primary treating physician
- Prior treatment with radiation or chemotherapy for endometrial cancer
Other illness
- Histologically confirmed high grade endometrioid or non-endometrioid type endometrial cancer (including serous, clear cell, carcinosarcoma or any mixed tumor containing these cell types)
- Evidence of deep myometrial invasion, cervical involvement or peritoneal disease on preoperative imaging
Other
- Any contraindication to lymph node mapping
Who the study is looking for
- Histologically confirmed low grade (grade 1-2) endometrioid type adenocarcinoma
- Candidate for surgery
- No evidence of deep invasion or peritoneal disease in patients that have undergone preoperative imaging
- Patients may have had prior hormonal treatment for the treatment of early endometrial neoplasia. Patients may not have had prior radiation or chemotherapy for treatment of endometrial cancer
- Patients must have a negative pregnancy if of childbearing potential
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.